Glaucoma Market Research Reveals Strong 5.3% CAGR Outlook Through 2030

The glaucoma market is poised for notable expansion in the coming years, driven by advances in technology and increasing awareness of eye health. Innovations in diagnostics, treatment options, and patient monitoring are paving the way for improved management of this vision-threatening condition. Let's explore the market size, key players, emerging trends, and major segments shaping the glaucoma landscape through 2030.

Projected Growth and Future Outlook for the Glaucoma Market
The glaucoma market is anticipated to grow significantly, reaching a valuation of $10.62 billion by 2030. This expansion reflects a compound annual growth rate (CAGR) of 5.3%. Several factors contribute to this robust growth, including technological progress in imaging techniques, surgical innovation advancements, enhanced digital monitoring of eye health, early detection programs, and increased investment in ophthalmology. Among the notable trends are the rising use of early diagnostic screening, broader adoption of combination drug therapies, growth in minimally invasive glaucoma surgeries, the spread of home-based eye monitoring solutions, and expanded patient education initiatives.

The glaucoma market size has grown strongly in recent years. It will grow from $8.2 billion in 2025 to $8.65 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to aging population, increased eye disease prevalence, advancement in ophthalmic diagnostics, early drug therapy adoption, growth of eye clinics.

Download a free sample of the glaucoma market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Key Drivers Accelerating Growth in the Glaucoma Market
Technological innovation plays a vital role in propelling the glaucoma market forward. Improvements in imaging and surgical techniques enable more precise diagnosis and treatment, which in turn increase patient outcomes and market demand. Digital eye health tools are also becoming more widespread, encouraging continuous monitoring and timely interventions.

At the same time, growing investments within ophthalmology are boosting research and development, facilitating early detection efforts and novel therapies. These factors combine to enhance overall glaucoma care, contributing to sustained market expansion throughout the forecast period.

View the full glaucoma market report:
https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Shaping the Glaucoma Industry
The glaucoma market features a number of prominent corporations shaping its development, including:
- Roche Holding AG
- Merck & Co. Inc.
- AbbVie Inc.
- Novartis AG
- Teva Pharmaceuticals Industries Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
- Bausch & Lomb Corp.
- Carl Zeiss Meditec
- Santen Pharmaceuticals Co. Ltd.
- Topcon Corporation
- Thea Laboratoires
- Corza Ophthalmology
- Lumenis Ltd.
- Alcon Inc.
- Glaukos Corporation
- Iridex Corporation
- Nova Eye Medical Ltd.
- Nidek Co. Ltd.
- Haag-Streit AG

In a strategic move in December 2024, Bausch + Lomb Corp., based in Canada, acquired Elios Vision Inc., a US company specializing in minimally invasive glaucoma surgery (MIGS) procedures. Though the deal amount was undisclosed, this acquisition opens doors to implant-free treatment options and reinforces Bausch + Lomb's commitment to providing comprehensive glaucoma solutions that better meet evolving patient and clinician needs.

Emerging Therapeutic Trends in the Glaucoma Market
Innovation remains a key focus for glaucoma market leaders, particularly in developing breakthrough drug therapies. One promising area is the advancement of Rho-kinase (ROCK) inhibitors, which act via a dual mechanism to lower intraocular pressure (IOP). These drugs improve fluid outflow through relaxation of trabecular meshwork cells, offering enhanced treatment efficacy.

As an example, in July 2023, Santen Pharmaceutical Co. Ltd. launched Roclanda in the UK. This fixed-dose combination (FDC) of latanoprost and netarsudil-the latter being a novel ROCK inhibitor-targets trabecular meshwork dysfunction to effectively reduce IOP. Roclanda is indicated for adults with primary open-angle glaucoma or ocular hypertension who have not achieved sufficient IOP control with monotherapy. The drug's introduction marks the first new class of glaucoma medication in 25 years, providing a significant breakthrough by combining two agents that boost outflow through both conventional and unconventional pathways, offering a comprehensive approach to managing elevated eye pressure.

Primary Segments Influencing Glaucoma Market Growth
This report segments the glaucoma market by several key categories:

1) Disease Type:
- Open Angle Glaucoma
- Angle Closure Glaucoma
- Other Disease Types

2) Diagnostic Methods:
- Tonometry
- Ophthalmoscopy
- Perimetry
- Gonioscopy

3) Drug Classes:
- Beta Blockers
- Prostaglandins
- Alpha Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- Other Drug Classes

4) Administration Routes:
- Oral
- Injections
- Intravitreal
- Other Administration Methods

5) End-User Settings:
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers

Further subsegments include:
- For Open Angle Glaucoma: Primary and Secondary Open Angle Glaucoma
- For Angle Closure Glaucoma: Primary and Secondary Angle Closure Glaucoma
- For Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

These classifications provide a detailed framework for understanding how various factors contribute to the growth and evolution of the glaucoma market as it advances toward 2030.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.